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Abstract
Background: Human genetics and host-associated microbial communities have been associated independently
with a wide range of chronic diseases. One of the strongest associations in each case is inflammatory bowel disease
(IBD), but disease risk cannot be explained fully by either factor individually. Recent findings point to interactions
between host genetics and microbial exposures as important contributors to disease risk in IBD. These include
evidence of the partial heritability of the gut microbiota and the conferral of gut mucosal inflammation by
microbiome transplant even when the dysbiosis was initially genetically derived. Although there have been several
tests for association of individual genetic loci with bacterial taxa, there has been no direct comparison of complex
genome-microbiome associations in large cohorts of patients with an immunity-related disease.
Methods: We obtained 16S ribosomal RNA (rRNA) gene sequences from intestinal biopsies as well as host
genotype via Immunochip in three independent cohorts totaling 474 individuals. We tested for correlation between
relative abundance of bacterial taxa and number of minor alleles at known IBD risk loci, including fine mapping of
multiple risk alleles in the Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene exon. We
identified host polymorphisms whose associations with bacterial taxa were conserved across two or more cohorts,
and we tested related genes for enrichment of host functional pathways.
Results: We identified and confirmed in two cohorts a significant association between NOD2 risk allele count and
increased relative abundance of Enterobacteriaceae, with directionality of the effect conserved in the third cohort.
Forty-eight additional IBD-related SNPs have directionality of their associations with bacterial taxa significantly
conserved across two or three cohorts, implicating genes enriched for regulation of innate immune response, the
JAK-STAT cascade, and other immunity-related pathways.
Conclusions: These results suggest complex interactions between genetically altered host functional pathways and
the structure of the microbiome. Our findings demonstrate the ability to uncover novel associations from paired
genome-microbiome data, and they suggest a complex link between host genetics and microbial dysbiosis in
subjects with IBD across independent cohorts.
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Crohn’s disease (CD) and ulcerative colitis (UC), collect-
ively known as inflammatory bowel disease (IBD), have
long been known to have genetic risk factors due to in-
creased prevalence in relatives of affected individuals as
well as higher concordance rates for disease among mono-
zygotic versus dizygotic twins. The sequencing of the hu-
man genome and subsequent large-cohort genetic studies
has revealed a complex set of polymorphisms conferring
varying levels of risk. Extensive analyses of these loci re-
vealed that impaired handling of commensal microbes
and pathogens is a prominent factor in disease develop-
ment [1]. For example, genetically driven impaired func-
tion of NOD2 in the sensing of bacterial products like
lipopolysaccharide may cause an increase in bacteria that
produce those products. Involvement of the JAK-STAT
pathway in immune responses, and involvement of the IL-
23-Th17 pathway in microbial defense mechanisms, are
also possible links between impaired immune response
and imbalances in bacterial assemblage [1-3]. These gen-
etic findings are in line with separate, independent tests of
microbial shifts associated with IBD. Shifts in taxonomic
composition and metabolic capabilities of the IBD micro-
biome are both now beginning to be defined [4-9]. Deter-
mining the extent and nature of host genome-microbiome
associations in IBD is an important next step in under-
standing the mechanisms of pathogenesis. Despite the
documented independent associations of IBD with herit-
able host immune deficiencies and with microbial shifts,
there has been limited study of the co-association of com-
plex host genetic factors with microbial composition and
metabolism in IBD patients or other populations [9-17],
and the mechanisms of host-microbiome disease pathways
are largely unknown.
Using three independent cohorts comprising 474 adult
human subjects with IBD aged 18 to 75 years, we tested
known IBD-associated host genetic loci for enrichment of
association with gut microbiome taxonomic composition.
Cohorts were located near Boston (USA), Toronto (Canada),
and Groningen (the Netherlands), with 152, 160, and 162
subjects, respectively. The cohorts contained 62.5%, 14.3%,
and 63.5% CD cases with the remainder cases of UC, and
31.5%, 11.3%, and 53.1% biopsies from inflamed sites, re-
spectively (detailed summary statistics by cohort and biopsy
location in Figures S1 and S2 in Additional file 1). The To-
ronto cohort contained 70.6% biopsies from the pre-pouch
ileum in subjects with previous ileo-anal pouch surgery; all
remaining samples were from the colon and terminal ileum,
with 73.0%, 18.1%, and 87.0% from the colon in the three
cohorts, respectively. We excluded all subjects that had
taken antibiotics within one month prior to sampling. We
obtained genotyping with Illumina Immunochip assays [18]
and 16S rRNA gene sequences as described previously [19]
(SNP prevalence by cohort in Additional file 2). We rarefied
bacterial microbiome samples to an even sequencing depth
of 2,000 sequences per sample to control for differential se-
quencing effort across cohorts. This rarefaction depth allows
us to observe taxa with relative abundance as low as 0.15%
with 95% confidence in each sample (binomial distribution
with 2,000 trials and probability 0.0015). We report a
pathway-level analysis of complex functional associations
between host genetics and overall microbiome composition,
as well as a targeted analysis of the association of NOD2
with specific bacterial taxa.
Methods
Ethics and consent
This study was approved by the Partners Human Re-
search Committee, 116 Huntington Avenue, Boston,
MA, USA. Patients gave informed consent to participate
in the study. This study conformed to the Helsinki Dec-
laration and to local legislation.
Data collection and generation
We genotyped subjects using the Immunochip platform
as described previously [18], excluding polymorphisms
with minor allele frequency of 0.1 or below from subse-
quent testing. 16S rRNA genes were extracted and ampli-
fied from intestinal biopsies and sequenced on the
Illumina MiSeq platform using published methods [20].
These procedures include extraction using the QIAamp
DNA Stool Mini Kit (Qiagen, Inc., Valencia, CA, USA) ac-
cording to the manufacturer’s instructions with minor al-
terations described in prior work [20], followed by
amplification using the 16S variable region 4 forward pri-
mer GTGCCAGCMGCCGCGGTAA and reverse primer
GGACTACHVGGGTWTCTAAT, followed by barcoded
multiplexing and sequencing. Only one biopsy was used
per subject; when multiple biopsies were available we se-
lected the non-inflamed biopsy first.
Data processing
We extracted risk allele counts for 163 published genetic
risk loci for CD, UC, and IBD [1]. When combining data
from separate Immunochip runs we tested for strand in-
versions by linkage disequilibrium with neighboring vari-
ants using plink [21]. Microbial operational taxonomic
units (OTUs) and their taxonomic assignments were
obtained using default settings in QIIME version 1.8 [22]
by reference-mapping at 97% similarity against representa-
tive sequences of 97% OTU in Greengenes (taxa version
4feb2011; metagenome version 12_10) [23]. We used all
default settings in QIIME 1.8 for OTU mapping, and we
used the pre-assigned taxonomy for the Greengenes OTU
representative sequences. Samples were rarefied to an
even sequence depth of 2,000 sequences per sample to
control for varied sequencing depth. Taxa were collapsed
into clusters with >0.95 Pearson’s correlation to remove
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coordinates of between-subject distances were obtained
from UniFrac [24] distances of OTUs and Jensen-Shannon
and Bray-Curtis distances of KEGG (Kyoto Encyclopedia of
Genes and Genomes) module and pathway distributions.
Bacterial taxa were arcsine-square-root transformed and
bacterial functions were power-transformed ('car' package
[25]) to stabilize variance and reduce heteroscedasticity.
Statistical analysis
Linear association tests were performed only within those
taxa with nonzero abundance in at least 75% of subjects.
Taxa below that threshold were subjected to logistic regres-
sion for presence/absence; no such taxa revealed significant
associations after correcting for multiple comparisons. To
ensure robustness of tests to outliers, subjects with taxon
or functional module relative abundance more than three
times the interquartile range from the mean were excluded
for tests of that feature. Power analysis was performed
using the linear effect size that we observed for Enterobac-
teriaceae when regressing on NOD2 risk allele count and
controlling linearly for clinical covariates (f
2=R
2/(1 - R
2)=
0.013; R is the coefficient of multiple correlation). Assum-
ing the need to correct for testing of all 163 IBD loci against
22 dominant taxa (3,586 tests; adjusted significance thresh-
old=1.39 ×10
-5), we would need at least 3,729 samples to
power the full analysis (R ‘pwr’ package power calculation
for a linear model with 19 numerator degrees of freedom).
Discrete qualitative covariates were re-coded with dichot-
omous dummy variables representing each class prior to
testing. Association of clinical covariates was performed
jointly by multiple linear regression. To overcome redun-
dancy between clinical covariates, we clustered clinical co-
variates based on their pairwise maximum uncertainty
coefficients [26], an information-theoretic measure of their
degrees of shared information. Continuous-valued covari-
ates were discretized prior to information-theoretic cluster-
ing. Complete-linkage clustering was performed to identify
groups of covariates in which each covariate contained at
least 50% of the information contained in each other covar-
iate. Network plots were created using the igraph [27] pack-
age. For the network plot of non-genetic host factors and
NOD2, width of edges was determined by the ratio of a
given covariate’s linear regression coefficient to the mean of
the regressed taxon’s relative abundance. Enrichment of a
host functional pathway for association with bacterial taxa
was assessed by comparing the observed rank product of
all host gene-bacterial taxon association tests for all genes
in the pathway with the distribution of rank products of
100,000 size-matched pathways randomly generated from
the null Immunochip variants described above. Prior to
testing, REACTOME pathways with >75% overlap were
binned and the largest constituent pathway chosen as a rep-
resentative for subsequent tests.
Results and discussion
Genotype-microbiome associations conserved across
independent cohorts
Our genotype-microbiome association testing methodology
included steps to overcome power limitations given the
very large number of potential comparisons, to incorporate
published knowledge of signaling and metabolic pathways
in the host genome, and to control for multiple environ-
mental host factors affecting gut microbiome composition
(Figure 1). In a targeted analysis of NOD2,w ea l s o
accounted for multiple causal variants in the genetic locus
(Supplementary methods in Additional file 1). After data
preprocessing and normalization we tested linearly for as-
sociation of risk allele count in each SNP with the relative
abundance of each bacterial taxon. In all tests, we con-
trolled for recent antibiotic usage (<1 month), recent im-
munosuppressant usage (<1 month), biopsy inflammation
status based on pathology, age, gender, biopsy location,
CD/UC diagnosis, disease location, elapsed time since diag-
nosis, cohort membership, and the first three principal
components of genotype variation (Figure 1; Figure S3 in
Additional file 1). Although the IBD-related SNPs extracted
from the Immunochip data were identified previously in
European populations, we do not expect this to limit our
findings because our cohorts were mostly of European des-
cent. We validated our linear testing methodology by com-
paring associations in the Boston cohort with those in the
other two cohorts, in addition to performing other sensitiv-
ity analyses (Supplementary methods in Additional file 1).
We tested 163 recently IBD-associated SNPs for associ-
ation with bacterial taxonomic profiles; 154 remained after
removing those with low minor allele frequencies or with
low call rates in our cohorts (Supplementary methods in
Additional file 1). Many of these SNPs have unknown
mechanisms and are likely only representative of a signal
within the surrounding genomic locus. Therefore, when a
single gene was associated previously with a SNP, we refer
to that SNP by the gene name for convenience. Due to
limited statistical power we were unable to perform a
full analysis of all possible SNP-taxon associations
(Supplementary methods in Additional file 1). However,
we were able to test for the robustness of microbiome-
wide associations with a given SNP by comparing the
directionality of the SNP-taxon coefficients between inde-
pendent cohorts. For this test we included only those
SNP-taxon associations for a given SNP that were nomin-
ally significant (P<0.05) in at least one of the studies be-
ing compared. We then obtained Matthew’sc o r r e l a t i o n
coefficient (MCC; also known as the phi coefficient) of the
signs (positive or negative) of the SNP-taxon coefficients
in one study with the signs of corresponding SNP-taxon
coefficients in the second study, and corrected these
microbiome-wide tests for multiple comparisons (one
MCC test per gene) at a false discovery rate (FDR) of 0.25.
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number of tests and the fact that we used the significant
results mainly to test for enrichment of certain host path-
ways, rather than to focus on individual associations. We
note that it is important to compare only the directionality
of SNP-taxon effects between studies, and not the magni-
tudes of the SNP-taxon regression coefficients, because
the magnitude of a coefficient is closely linked to the
mean relative abundance of a given taxon. To decrease
bias toward a particular taxonomic level of association
[28], we performed these tests using bacterial taxa at all
taxonomic levels from phylum to genus, collapsing those
with redundant signals. In contrast to using OTU clusters,
binning by taxonomy allows inherent flexibility in the level
of 16S gene sequence identity within each bin in different
lineages.
A number of host genes, some with known involvement
in microbial handling, and others with unknown function,
demonstrated reproducible effects on the taxonomic struc-
ture of the microbiome across two or more cohorts. Effect
size and directionality of genotype-microbiome associations
were highly reproducible between cohorts in the case of
NOD2 and 48 other host genes (FDR <0.25; Additional
file 4). NOD2 had one of the most highly reproducible sets
of associations with bacterial taxa (MCC=0.75, FDR =2.6 ×
10
-4 comparing Boston versus Toronto cohorts; MCC=
0.85, FDR = 7.7 × 10
-4 Boston versus Netherlands; Figure 2a).
Other genes with significantly conserved directionality of ef-
fects on bacterial taxa between at least one pair of studies
included tumor necrosis factor (ligand) superfamily, mem-
ber 15 (TNFSF15; MCC =0.87, FDR= 9.5× 10
-3,B o s t o n
versus Netherlands) and subunit beta of interleukin 12
(IL12B; MCC=0.74, FDR=1.5×10
-3,B o s t o nv e r s u s
Netherlands).
NOD2 variants were the first genetic associations iden-
tified in CD, and they remain some of the strongest risk
factors. NOD2-driven murine dysbiosis causes inflamma-
tion even when the dysbiotic microbiota are transplanted
into a wild-type mouse [13]. Expression of TNFSF15,a
member of the tumor necrosis factor ligand superfamily,
causes proinflammatory cytokine production, and is spe-
cifically expressed more highly in the gut in IBD patients
compared with healthy controls. Interestingly, a receptor
for a member of the same family, TNFSF14, enhances
immune response to pathogenic bacteria via signal trans-
ducer and activator of transcription 3 (STAT3) activation
Figure 1 Schematic of multiomics genotype-microbiome association testing methodology. Host genome-microbiome association testing involves
potentially thousands or millions of genetic polymorphisms and hundreds or thousands of bacterial taxa and genes. Full feature-by-feature association testing
is likely to be underpowered in all but the largest cohorts or meta-analyses; therefore, our methodology includes careful feature selection from bothd a t a
types. Raw genetic polymorphisms were derived from Immunochip data and filtered by known IBD associations from a large-cohort GWAS study [1].
Microbiome sequences were binned by lineage at all taxonomic levels. After data normalization and filtering (see Methods), a simple linear test was
performed for association between minor allele count and bacterial taxon relative abundance while controlling for clinical covariates. QTL, quantitative
trait loci.
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and TNFSF15 are known to share an alternative recep-
tor, indicating potential functional overlap. IL12B forms
part of the interleukin-23 complex, involved in microbial
defense mechanisms through the IL23-Th17 pathway.
Immunity-related host functional pathways linked to
microbiome profile
We hypothesized that host functional pathways containing
multiple risk variants related to microbial handling and in-
nate immune response would be associated with micro-
biome features. To test this hypothesis we performed a
functional enrichment analysis on the 49 genes identified
to have conserved microbiome associations across co-
horts. We found these genes to be significantly enriched
for regulation of innate immune response (FDR=2.31×
10
-6, hypergeometric enrichment test), inflammatory re-
sponse (FDR=7.43×10
-6, hypergeometric enrichment
test), and participation in the JAK-STAT cascade (FDR=
2.04×10
-4, hypergeometric enrichment test) (Figures 3
and 4; Additional file 5). A gene-gene interaction network
analysis also implicated STAT3, interleukin-12 subunit
alpha (IL12A), and interleukin-23 subunit alpha (IL23A)i n
the network of associated genes.
STAT3 and TNFSF15 are both implicated in IL23 sig-
naling. STAT3 works in concert with Janus Kinase 2
(JAK2) in the JAK-STAT pathway to drive immune re-
sponse to pathogenic infection. STAT3 also regulates T
helper 17 (Th17) cell differentiation by binding IL23 re-
ceptor (IL23R; risk variant for IBD: rs11209026) and
RAR-related orphan receptor C (RORC; rs4845604),
both of which are located in IBD risk loci. STAT3 defects
have also been implicated recently in skin microbial im-
balance and impaired host defense. TNFSF15, a member
of the tumor necrosis factor ligand superfamily, is a cost-
imulator of T cells, and is specifically expressed more
highly in the gut in IBD patients compared with healthy
controls [31,32].
Fine mapping of NOD2 locus reveals association with
Enterobacteriaceae
Based on previous results [9-13] and on the strong linkage
between NOD2 and microbial handling [9,12,13], we con-
tinued with a targeted analysis of NOD2 association with
specific microbial taxa and functions (Additional file 6).
Figure 2 NOD2 fine mapping reveals association with taxonomic and metabolic dysbiosis. (a) Scatterplot of NOD2-bacterial taxon regression
coefficients in one study versus the corresponding regression coefficients in another study. We included only those taxa with a nominally significant (P<0.05)
association in a least one of the cohorts being compared. (b) Comparison of residual distributions of Enterobacteriaceae with and without incorporating the
six independent known causal NOD2 variants; considering variant rs5743293, only 6.3% of subjects have one or more risk alleles; aggregating risk allele counts
across the six variants increases this to 21.8%, and reveals much stronger associations with the microbiome. The strip charts and violin plots show the
distribution of standardized residual relative abundance of Enterobacteriaceae versus NOD2 risk allele dosage after data transformation and regression on
clinical covariates. Violin plots show the conditional density of residual relative abundance within each dosage level. (c) Relative positions of six NOD2 variants
in NOD2 exons [29].
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across six known causal variants: rs2066844 (R702W),
rs2066845 (G908R), rs5743277, rs5743293 (fs1007insC),
rs104895431 and rs104895467 [29]. This novel method-
ology was crucial as individual variants contained only
part of the signal (Figure 2b,c). NOD2 was associated with
the first principal axis of taxonomic (via weighted UniFrac
distances) microbiome variation (FDR <0.05, controlling
for three principal axes tested), linking NOD2 to shifts in
overall microbiome taxonomic composition. We identified
increased Enterobacteriaceae in subjects with higher
NOD2 risk allele dosage (FDR=0.11, controlling for mul-
tiple taxa tested; Figure 2b; Additional file 7). An increase
in Gammaproteobacteria is a known component of IBD
dysbiosis and is associated with inflammation in mice and
humans [4,33] and with increased epithelial penetration in
CD and UC [34]. NOD2 also had one of the most strongly
reproducible associations with microbiome composition
when comparing cohorts. Although NOD2 is only associ-
ated with increased risk of CD, NOD2-microbiome associ-
ations we observed were generally independent of CD/UC
diagnosis, with high overlap between CD and UC when
tested separately (taxa: Spearman’s rho =0.57, P=6 .5×1 0
-3;
Figure S4 in Additional file 1). This implies that the associ-
ation may be disease-independent, and may play a role in
pathogenesis only in subjects with other risk factors. For
example, NOD2 SNP rs5743293 is associated with
complications in ileo-anal pouch patients despite their ori-
ginal diagnosis being UC [35-38].
A complex web of genotype-environment-microbiome
interactions in IBD
Our findings indicate that host genetics are part of a com-
plex web of host-associated factors influencing micro-
biome composition. We performed a meta-analysis of
interactions between clinical host factors and bacterial
taxa using the above 474 subjects and an additional 55
subjects who had recently taken antibiotics. This analysis
included NOD2 as one of the host factors. We identified
an additional 99 significant associations of non-genetic
factors with relative abundance of specific bacterial taxa,
largely in agreement with previous analyses of the IBD
microbial environment [4]. To visualize the overlap of in-
teractions between various host factors and microbial
taxa, we constructed a network of associations between
bacterial taxa and observed host and environmental fac-
tors (Figure 5; Additional file 8; Supplementary methods
in Additional file 1).
This analysis revealed a web of complex overlapping link-
ages between numerous host factors and bacterial taxa. For
example, recent antibiotic usage is associated with system-
atic shifts in many major taxonomic groups (Figure 6; FDR
<0.05); immunosuppressants are associated with decreased
Firmicutes, and Ruminococcaceae. Biopsy location and
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Figure 3 Host genes with reproducible microbiome associations across cohorts. Network analysis of host signaling and metabolic pathways
enriched for association with microbial taxa (FDR <0.25, Matthew’s correlation test). The visualization of gene-gene interaction network for the
subset of 49 genes with significantly conserved directionalities of association with the microbiome is supported by several types of gene-gene
connection [30]. This enrichment analysis identified enriched functional networks in innate immune response, inflammatory response, and the
JAK-STAT pathway, all of which play roles in immune response to pathogen infection [1].
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and disease phenotype had measurable, although less broad,
effects; genotype, as represented by the NOD2 subtype, had
a modest effect in relation to other factors. Inflammatory
status of the biopsied tissue was associated with increased
relative abundance of unclassified members of Lactobacillus,
and with decreased relative abundance of Bacteroides unifor-
mis (Figure S5 in Additional file 1). This analysis demon-
strates the comprehensive and intermingled effects of
treatment history, gastrointestinal biogeography, and other
host and environmental factors on gut microbiome profile
and makes clear the need to account for host factors when
linking host genotype to microbial composition in a pheno-
typically heterogeneous population. We confirmed that host
genetics as a whole do have a significant effect on micro-
biome profile by correlating overall between-subject genetic
distance (Manhattan distance) with overall between-subject
microbiome distance (unweighted UniFrac distance)
(P<5.0×10
-10; Figure S6 in Additional file 1), but that it is
only a minor contributor in the context of other sources of
variation. A recent study of treatment-naïve pediatric pa-
tients with CD identified consistent microbiome shifts in pa-
tients with recent antibiotic exposure toward the disease-
related state [20]. That study exemplified the need to control
for the potentially confounding effects of antibiotics when
attempting to identify bacterial profiles associated with dis-
ease. Based on several studies linking short- and long-term
dietary exposure to microbiome profile, it is also likely to be
useful to include food intake diaries or dietary recall ques-
tionnaires in future genotype-microbiome research [39,40].
Antibiotics contribute to IBD dysbiosis independent of
NOD2 effects
The fact that host genetics are a minor contributor to
overall microbiome composition relative to environmental
factors does not exclude the possibility that genotype-
microbiome interactions play an important role in the eti-
ology of IBD; it is possible that the important variations
are in a particular set of taxa or a particular set of func-
tions (for example, resistance to oxidative stress) that
make up a minor portion of the overall microbiome, while
there are other taxa not closely related to IBD but highly
influenced by the host’s environmental exposures (for ex-
ample, dietary exposures). Such a subset of taxa related to
dysbiosis were reported in a recent comparison between
treatment-naïve patients with Crohn’s disease and healthy
controls [20], and the ratio of the disease-associated taxa
to the health-associated taxa was referred to as the
Figure 4 Top gene-bacteria associations. Beeswarm plots of the relative abundance of six bacteria stratified by the number of risk alleles present in
SNPs in the given genes. The associations shown are the six most significant associations between bacteria and genes in the subset of genes with
conserved bacterial associations across cohorts and belonging to the JAK-STAT pathway or the innate immune pathway response as shown in Figure 3.
Relative abundances shown are transformed with the arcsine-square root transformation to stabilize variance and to make distributions more normal.
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fied an increase in the MDI scores of patients who had re-
cently received antibiotics, indicating that antibiotics tend
to shift patient microbiomes further into the realm of
IBD-related dysbiosis. We used the same taxa as reported
previously to calculate an MDI score for each patient in
our analysis. In our cohorts we confirmed the published
finding that, when controlling for NOD2 effects on micro-
biome structure, MDI score tended to be higher in pa-
tients with recent usage (within less than one month) of
antibiotics (P=0. 03 9,t-test of linear regression coefficient)
(Figure 6). This finding, together with previously pub-
lished findings regarding the effects of antibiotics on the
IBD microbiome suggest that antibiotics and duration of
disease are additional risk factors for IBD-related
dysbiosis.
Conclusions
Taken together, our findings indicate a complex set of
associations between the mucosal-adherent microbiome
and genetic impairment of several host immune path-
ways. Although we have been living and evolving with
our microbial symbionts throughout human evolution,
we have only been aware of their existence for a few
centuries, and the genetic and functional diversity of our
so-called 'second genome' has only become apparent in
the last few decades. Also in recent decades incidence of
IBDs and other autoimmune and autoinflammatory dis-
eases has increased dramatically [42], and a rapidly
growing set of these diseases has been linked to shifts
both in taxonomic carriage and functional potential of
host-associated microbial communities. Although our
data are cross-sectional and therefore cannot define
Figure 5 Host factors associated with the IBD microbiome. A complex network of host factors associated with the IBD microbiome
(all associations FDR <0.05); only taxa with at least four significant associations are included in the network; green and purple edges indicate
positive and negative associations, respectively; the width of an edge indicates the strength of the association. The effects of these factors on
individual taxa are highly overlapping. The analysis identified covariates representing each type of host factor, consistent with previous results [4].
Biopsy location and medication history had the strongest and most comprehensive effects on microbiome profile; the effect of NOD2 was moderate
in comparison. Cohort membership (not shown) also affected microbiome profile. These results demonstrate the need for study designs and analysis
methodologies that control carefully for numerous host genetic and environmental factors when performing microbiome-based biomarker discovery.
Abx, antibiotics within 1 month; Imm, immunosuppressants within 1 month; L2, no ileal involvement; PPI, biopsy from pre-pouch ileum.
Figure 6 Association of IBD-related dysbiosis and recent antibiotics
usage. A beeswarm plot [41] of the previously published microbial
dysbiosis index [20] (MDI) stratified by recent antibiotics usage by patients.
The test for this association between MDI and antibiotics (P=0.039, linear
regression t-test) included NOD2 risk allele count to control for the effects
of NOD2 genetics on the microbiome.
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associations with taxonomic and metabolic dysbiosis in
humans. These include implications of microbiome-wide
associations with TNFSF15, IL12B, and with innate
immune response, inflammatory response, and the JAK-
STAT pathway, as well as NOD2-related increases in En-
terobacteriaceae relative abundance. Future studies may
be warranted to account for the effects of copy number
variation, pleiotropic genes and epigenetic modifications.
It is also possible that certain genotype-microbiome as-
sociations observed in IBD patients may be disease-
independent and may be relevant to healthy individuals
and individuals with other diseases. The methods we
employed were validated on independent cohorts and
make possible well-powered false-positive-controlled
testing of microbiome-wide host genetic associations.
Accession numbers
16S rRNA sequences and Immunochip genotyping have
been deposited at the National Center for Biotechnology
Information as BioProject with top-level umbrella project
ID PRJNA205152.
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